Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced the completion of a $10 million common share sale through its ATM program, with 3,564,228 shares sold to EcoR1 Capital and 35,714 shares to CEO Richard A. Miller at $2.80 per share. The settlement is set for May 6, 2021. This follows an effective shelf registration statement declared on March 19, 2020. Investors are encouraged to review the related prospectus available on the SEC's EDGAR database or by contacting Jefferies LLC directly. The company is focused on advancing its clinical programs, including CPI-006 and CPI-818.
Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and reported Q1 2021 financial results. The company is advancing its Phase 3 trial for CPI-006 in hospitalized COVID-19 patients, with full enrollment expected by year-end. Financially, Corvus reported cash and equivalents of $68 million, up from $44.3 million in Q4 2020, aided by a $32 million equity offering. R&D expenses decreased to $8.2 million, while the net loss narrowed to $11.6 million. Corvus is also progressing with CPI-818 and ciforadenant clinical trials, showcasing potential in cancer treatments.
Corvus Pharmaceuticals (CRVS) reported a business update and financial results for Q4 and the full year of 2020. They initiated a Phase 3 study for CPI-006 targeting COVID-19, which showed promising Phase 1 results with no patients requiring mechanical ventilation. Additionally, Corvus co-founded Angel Pharmaceuticals to expedite drug development in China. Financially, they ended 2020 with $44.3 million in cash, down from $78.0 million in 2019 and projected a cash burn of $46-$48 million for 2021. The company reported a net income of $27.1 million for Q4 2020.
BURLINGAME, Calif., March 05, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced participation in two investor conferences this March. The H.C. Wainwright Global Life Sciences Conference is scheduled for March 9-10, 2021, featuring pre-recorded presentations and one-on-one meetings. A corporate overview by Dr. Richard A. Miller will be available on-demand starting March 9. The 33rd Annual Roth Virtual Conference follows on March 15-17, where Dr. Miller will engage in a fireside chat on March 16 and present additional insights. Webcasts will be accessible through the Corvus website.
Corvus Pharmaceuticals (NASDAQ:CRVS) completed an underwritten public offering of 9,783,660 shares at $3.50 per share, raising gross proceeds of $34.2 million. This includes 1,212,231 shares from underwriters’ partial exercise of their option. The net proceeds for Corvus stand at approximately $31.8 million after expenses. Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are the joint book-running managers for the offering. The shares' offering was made under an effective registration statement with the SEC.
Corvus Pharmaceuticals (NASDAQ:CRVS) has announced the pricing of a public offering of 8,571,429 shares of common stock at $3.50 per share, totaling gross proceeds of $30 million. The offering will support the Phase 3 clinical trial of CPI-006 and the development of other product candidates. Additionally, underwriters have a 30-day option to purchase an extra 1,285,714 shares. The offering is set to close around February 17, 2021, pending customary closing conditions.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced a public offering of its common stock, with all shares being sold by the company. Underwriters may purchase an additional 15% of the shares offered. The company plans to utilize the net proceeds for its Phase 3 clinical trial of CPI-006 and other product developments. The offering is subject to market conditions, and a registration statement for these securities was filed with the SEC.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 3 clinical trial for CPI-006, targeting hospitalized COVID-19 patients. This randomized, double-blind, placebo-controlled study aims to enroll around 1,000 participants globally, with results expected in Q4 2021. Preliminary Phase 1 results showed promising outcomes, with no patients progressing to mechanical ventilation and a median hospital discharge time of 3.5 days. CPI-006 aims to stimulate B cells for enhanced antibody production, potentially addressing SARS-CoV-2 variants. A separate Phase 2 trial is planned for CPI-818 in T-cell lymphoma.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported new interim data on CPI-818 at the 62nd ASH Annual Meeting, showcasing its potential in treating T cell lymphomas and autoimmune lymphoproliferative syndrome (ALPS). The Phase 1/1b trial revealed promising anti-tumor activity, with significant tumor responses in advanced T cell malignancies. No severe treatment-related adverse events were recorded. Additionally, pre-clinical data indicated that CPI-818 could inhibit abnormal T cell activation in ALPS patients. The company plans to continue its studies and collaborate with Angel Pharmaceuticals in China.
Corvus Pharmaceuticals (CRVS) has announced new findings on its drug CPI-818 at the upcoming 62nd ASH Annual Meeting. The data includes results from a Phase 1/1b trial focused on T cell lymphoma and pre-clinical studies for treating autoimmune lymphoproliferative syndrome (ALPS). CPI-818 is an ITK inhibitor showing potential in blocking T cell activation in ALPS patients. Presentations will occur on December 5 and 6, 2020, highlighting CPI-818's efficacy and safety.